EMJ Oncology 5.1 2017

This interactive article summarises key discussions from GSK sponsored symposia that took place during the ESCMID Global Congress 2024, held from 27–30th April 2024 in Barcelona, Spain. Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content. Thank you! Please share some more information on the rating you have given Submit Feedback

Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content. Thank you! Please share some more information on the rating you have given Submit Feedback

Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content. Thank you! Please share some more information on the rating you have given Submit Feedback

Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cancer cases per year.1 According to the Spanish… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content. Thank you! Please share some more information on the rating you have given Submit Feedback